Qiagen (QGEN) Beat Its Own Guidance, So Why Did Margins Slip?

Qiagen (QGEN) exceeded its own expectations for the second quarter of 2026, surprising investors with flat net sales of $535 million and adjusted diluted EPS of $0.62. While beating a cautious bar for a company navigating through discontinued product lines is noteworthy, the real intrigue lies in how new launches will drive growth in the second half of the year.

The company's growth pillars expanded 5% at constant exchange rates, with Sample Technologies leading the charge at 9% CER growth, driven by automated consumables and higher instrument sales. QIAcuity, a digital PCR platform, also contributed to growth with double-digit consumables sales. Qiagen's recent product activity includes the launch of QIAsymphony Connect, QIAsprint Connect placements, and two new bloodstream infection panels for QIAstat, all making strides in Europe with FDA approval anticipated by year-end.

However, the flat top line hides uneven performance, with diagnostic solutions declining 2% and PCR sales falling 8%, negatively impacted by prior-year comparisons in respiratory testing. Profitability also suffered, with adjusted operating income down 2% and adjusted gross margin declining to 66.2% due to shifts in product mix.

EMEA sales fell 2% CER, and Asia Pacific sales slipped by 2% CER as well. Inventory days outstanding rose to 153 from 149 due to stockpiling for upcoming launches. Management now expects a turnaround from roughly negative 1% CER sales growth in the first half to 3% to 4% in the second half, contingent on new products, easier comparisons, and the successful execution of discontinued lines.

Hedge fund ownership rose from 22 to 39 quarter-over-quarter, indicating growing institutional interest. Despite the stock trading below a forward P/E of 13.79, suggesting cautious optimism, Qiagen's second-half growth hinges on a carefully timed sequence of launches, improved comparisons, and the timely contributions of Parse and QuantiFERON.

While acknowledging the potential of QGEN, some analysts suggest exploring other AI stocks as potential investment opportunities.